Back to results
US 2021/0332382 A1Published application
Cancer therapy
AssigneeValo Therapeutics Oy
InventorsTuuli Ranki, Sari Pesonen, Petri Priha, Erkko Ylösmäki, Vincenzo Cerullo, Beatriz Martins
Life of this patent
Estimating the term…
Abstract
The invention concerns a modified oncolytic adenovirus; a pharmaceutical composition comprising same; and a method of treating cancer using same.
Claims25
A modified adenovirus comprising:
- at least one of the following polypeptides attached covalently or non-covalently onto the viral capsid without having been genetically encoded by said adenoviral vector
- i) VFGIELMEVDPIGHLYIFAT [SEQ ID NO:1];
- ii) YLAMPFATPMEAELARRSLA [SEQ ID NO:2];
- or
- iii) a polypeptide that is at least 90% identical therewith.
2 more elements
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.